Mario Gabelli’s Gamco Investors, Inc Et Al Opened Huge Bioscrip, Inc Position

August 11, 2017 - By Richard Conner

 Mario Gabelli's Gamco Investors, Inc Et Al Opened Huge Bioscrip, Inc Position

Investors sentiment decreased to 0.89 in 2016 Q4. Its down 0.57, from 1.46 in 2016Q3. It turned negative, as 18 investors sold BioScrip Inc shares while 29 reduced holdings. 16 funds opened positions while 26 raised stakes. 91.55 million shares or 0.99% less from 92.47 million shares in 2016Q3 were reported.

Illinois-based Envestnet Asset Management has invested 0% in BioScrip Inc (NASDAQ:BIOS). Northern Trust invested in 0% or 1.24 million shares. Credit Suisse Ag stated it has 48,879 shares or 0% of all its holdings. Millennium Management Ltd invested in 607,832 shares or 0% of the stock. Voya Invest Mngmt Ltd Liability Corporation holds 0% of its portfolio in BioScrip Inc (NASDAQ:BIOS) for 35,932 shares. Alliancebernstein L P invested in 0% or 94,100 shares. Parametric Portfolio Assocs Lc holds 0% or 199,043 shares in its portfolio. Kcg holds 0% or 75,871 shares. 482,700 are held by California Pub Employees Retirement Systems. Marathon Management invested in 0.07% or 145,850 shares. Pioneer Inv Mngmt reported 0% of its portfolio in BioScrip Inc (NASDAQ:BIOS). Blackrock Advsrs Ltd Liability Corp accumulated 57,715 shares. Sheets Smith Wealth Mgmt, North Carolina-based fund reported 82,510 shares. Amer Interest, New York-based fund reported 39,025 shares. State Board Of Administration Of Florida Retirement Sys reported 67,104 shares or 0% of all its holdings.

The New Mario Gabelli’s Gamco Investors, Inc Et Al Holding in Bioscrip, Inc

Gamco Investors, Inc Et Al reported SC 13D/A form with the SEC for Bioscrip, Inc. Access it here: 000080724917000129. As reported by Mario Gabelli’s Gamco Investors, Inc Et Al, the filler owns 8.02% or 10,228,742 shares of the Health Care–company.

Bioscrip, Inc stake is new for [reportingPerson]. Date of activity: August 10, 2017. This shows Mario Gabelli’s Gamco Investors, Inc Et Al’s positive view for Bioscrip, Inc.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Mario Gabelli’s Gamco Investors, Inc Et Al’s portfolio is in the sector.

Bioscrip, Inc Institutional Sentiment

Filings show 99 investors own Bioscrip, Inc. The ownership in Q3 2015 is high, at 51.49 % of the outstanding shares. This is increased by 1860507. 65635275 were owned by these investors. 13 funds opened new Bioscrip, Inc stakes, 37 increased positions. There were 19 that closed positions and 32 reduced them.

Phil Frohlich Prescott Group Capital Management Llc is an investor bullish on Bioscrip, Inc, owning 2291529 shares as of Q3 2015 for 1.03% of its portfolio. Nelson Obus Wynnefield Capital Inc owns 1380000 shares or 1.03% of its portfolio. CT Coliseum Capital Management Llc have 1.07% of its portfolio for 1422410 shares. Further, Ardsley Advisory Partners reported stake worth 2.09% of its portfolio. The NY Roanoke Asset Management Corp owns 287002 shares. Bioscrip, Inc is 0.20% of its portfolio.

Business Profile

BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

SEC Form 13D.

Wall Street await BioScrip Inc (NASDAQ:BIOS) to release earnings on August, 14. Analysts forecast EPS of $-0.10, down exactly $0.02 or 25.00 % from 2014’s $-0.08 EPS. After posting $-0.16 EPS for the previous quarter, BioScrip Inc’s analysts now forecast -37.50 % EPS growth.

The stock increased 5.19% or $0.16 during the last trading session, reaching $3.24. About 2.43M shares traded or 105.93% up from the average. BioScrip Inc (NASDAQ:BIOS) has declined 29.17% since August 11, 2016 and is downtrending. It has underperformed by 45.87% the S&P500.

BioScrip, Inc. is engaged in providing infusion solutions. The company has market cap of $413.02 million. The Firm partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. It currently has negative earnings. The Firm operates through Infusion Services segment.

BioScrip Inc (NASDAQ:BIOS) Ratings Coverage

Among 6 analysts covering BioScrip (NASDAQ:BIOS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioScrip has $4.50 highest and $300 lowest target. $3.90’s average target is 20.37% above currents $3.24 stock price. BioScrip had 10 analyst reports since August 11, 2015 according to SRatingsIntel. On Tuesday, July 25 the stock rating was maintained by Jefferies with “Buy”. The rating was initiated by Lake Street on Tuesday, January 3 with “Buy”. As per Thursday, August 10, the company rating was upgraded by SunTrust. On Thursday, June 8 the stock rating was maintained by Jefferies with “Buy”. The stock of BioScrip Inc (NASDAQ:BIOS) has “Buy” rating given on Tuesday, August 11 by SunTrust. Jefferies maintained BioScrip Inc (NASDAQ:BIOS) rating on Wednesday, August 9. Jefferies has “Buy” rating and $400 target. The stock of BioScrip Inc (NASDAQ:BIOS) earned “Buy” rating by Dougherty & Company on Wednesday, August 12.

More important recent BioScrip Inc (NASDAQ:BIOS) news were published by: Reuters.com which released: “BRIEF-BioScrip qtrly loss per share $0.26” on August 08, 2017, also Nasdaq.com published article titled: “BioScrip Applauds US House Passage of HR3178, the Medicare Part B Improvement …”, Globenewswire.com published: “BioScrip To Host Second Quarter Results Call” on July 17, 2017. More interesting news about BioScrip Inc (NASDAQ:BIOS) was released by: Nasdaq.com and their article: “BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife” with publication date: August 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.